

AUG 3 0 2001

1K010968

510 (k) Summary of Safety and Effectiveness for VectorVision® CT/Fluoro

Manufacturer:

Address:

BrainLAB AG
Ammerthalstrasse 8
85551 Heimstetten
Germany
Phone: +49 89 99 15 68 0
Fax: +49 89 99 15 68 33

Contact Person:

Mr. Rainer Birkenbach

Summary Date:

March 16, 2001

Device Name:

Trade name:

VectorVision® CT/Fluoro

Common/Classification Name:

VectorVision, BrainLAB Image Guided Surgery System / Instrument,
Stereotaxic

Predicate Device:

Vector Vision® 2 (K 983831)

Vector Vision® Spine (K 981508)

Device Classification Name: Instrument, Stereotaxic

Regulatory Class: Class II

Intended Use:

BrainLAB VectorVision® is intended to be an intraoperative image guided localization system to enable minimally invasive surgery. It links a freehand probe, tracked by a passive marker sensor system to virtual computer image space on a patient's preoperative image data being processed by a VectorVision workstation. The system is indicated for any medical condition in which the use of stereotactic surgery may be appropriate and where a reference to a rigid anatomical structure, such as the skull, a long bone, or vertebra, can be identified relative to a CT, X-ray or MR based model of the anatomy.

Example procedures include but are not limited to:

Spinal Procedures:

Spinal implant procedures such as pedicle screw placement.

Device Description:

VectorVision® CT/Fluoro Module is part of the VectorVision² Spine Software and intends to enable "touchless" patient registration for operational planning and navigation in surgery. It allows using intra-operatively acquired x-ray data for registering a patient's pre-operatively acquired CT data being processed by a VectorVision workstation.

The VectorVision® CT/Fluoro Module uses intra-operatively acquired x-ray images and their defined exact spatial position in relation to the patient. By using pre-operatively acquired CT data the software is able to match CT and x-ray data. It compares the gray scale gradients of anatomical structures in both data sets and optimizes their correlation during a matching process.

After this matching the spatial orientation of the pre-operatively acquired CT data has been defined by using the exact spatial position information of intra-operatively acquired x-rays.

Substantial equivalence:

VectorVision® CT/Fluoro Module has been verified and validated according to BrainLAB's procedures for product design and development. The validation proves the safety and effectiveness of the system. The information provided by BrainLAB in this 510 (k) application was found to be substantially equivalent with the predicate device VectorVision²® (K983831) and VectorVision® Spine Software (K981508).



AUG 3 0 2001

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Rainer Birkenbach
Executive Vice President
BrainLab, AG
Ammerthalstrasse 8
85551 Heimstetten
Germany

Re: K010968
Trade/Device Name: VectorVision CT/Fluoro
Regulation Number: 882.4560
Regulatory Class: II
Product Code: HAW
Dated: June 25, 2001
Received: June 27, 2001

Dear Mr. Birkenbach:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten, Ph.D., M.D.", with a stylized flourish at the end.

Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): K010968Device Name: VectorVision CT/Fluoro**Indications For Use:**

BrainLAB VectorVision is intended to be an intraoperative image guided localization system to enable minimally invasive surgery. It links a freehand probe, tracked by a passive marker sensor system to virtual computer image space on a patient's preoperative image data being processed by a VectorVision workstation. The system is indicated for any medical condition in which the use of stereotactic surgery may be appropriate and where a reference to a rigid anatomical structure, such as the skull, a long bone, or vertebra, can be identified relative to a CT, X-ray or MR based model of the anatomy.

Example procedures include but are not limited to:

Spinal Procedures:

Spinal implant procedures such as pedicle screw placement.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

(Optional Format I-2-96)

812

(Division Sign-Off)
Division of General, Restorative
and Neurological Devices

510(k) Number K010968